Ductal adenocarcinoma of the pancreas remains one of the most lethal malignancies, with a global 5-year survival rate below 10% and a median recurrence-free survival of less than 14 months after resection. Despite progress in surgery and adjuvant therapies, the tumor’s aggressiveness and resistance to standard chemotherapy make it a diagnosis that continues to defy therapeutic advances. These challenges have led researchers to focus increasingly on immunotherapy—particularly the use of therapeutic vaccines.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
